Ki20227
Product Specifications
UNSPSC Description
Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction[1].
Target Antigen
c-Fms; c-Kit; PDGFR; VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Ki20227.html
Purity
99.30
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=C(C=C1OC)OC2=CC=NC3=CC(OC)=C(C=C23)OC)NC(C)C4=NC=CS4
Molecular Weight
480.54
References & Citations
[1]Ohno H, et al. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5(11):2634-43.|[2]Boru Hou, et al. Ki20227 influences the morphology of microglia and neurons through inhibition of CSF1R during global ischemia. Int J Clin Exp Pathol. 2016;9(12):12459-12469.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-10408/Ki20227-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-10408/Ki20227-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
623142-96-1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1173313 Inquire
Recombinant Cryptococcus neoformans var. neoformans serotype D Polyadenylation factor subunit 2 (PFS2), partial
Ask
View Details 
